Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCES

Panelists discuss key insights on the importance of early screening for T1D, the role of antibody testing in identifying at-risk individuals, and the need for timely intervention to preserve ß-cell function and optimize long-term management strategies for better patient outcomes.

Panelists discuss how teplizumab infusion requires specialized medical facilities equipped to manage intravenous therapy, monitor for potential adverse effects, and provide appropriate care during treatment to ensure patient safety and efficacy.

Panelists discuss how teplizumab, an anti-CD3 monoclonal antibody, delays the onset and progression of type 1 diabetes by modulating immune response and preserving ß-cell function in high-risk individuals.

Panelists discuss screening for T1D for individuals at higher risk, such as those with a family history of T1D, autoimmune conditions, or certain genetic markers, to identify early signs of the disease and enable timely intervention.

Panelists discuss how antibody screening tests for type 1 diabetes (T1D), including tests for insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD) antibodies, and other markers can help identify individuals at risk for developing the disease before clinical symptoms appear, enabling earlier monitoring and potential intervention.

Panelists discuss how delaying intervention in stage 2 type 1 diabetes, when dysglycemia is present but clinical symptoms have not yet developed, can lead to further ß-cell deterioration and worsen long-term glycemic control, ultimately increasing the risk of complications.

Panelists discuss how the progression of type 1 diabetes unfolds through distinct stages, from the preclinical phase of autoimmunity to the onset of clinical diabetes, emphasizing the importance of early detection and intervention to improve patient outcomes.

Panelists discuss how adhering to screening guidelines for type 1 diabetes enables early detection and intervention, improving patient outcomes and delaying disease progression through timely treatments like teplizumab.

Panelists discuss how managing the clinical, financial, and quality-of-life burdens of type 1 diabetes (T1D) requires early intervention, proactive care strategies, and the use of treatments like teplizumab to improve patient outcomes and reduce long-term complications.

Panelists discuss how antibody screening for type 1 diabetes can identify at-risk individuals early, enabling proactive monitoring and intervention to delay or prevent disease onset.

Panelists discuss how teplizumab therapy can delay the onset and progression of type 1 diabetes (T1D) by preserving β-cell function and reducing the risk of developing full-blown diabetes in at-risk individuals.

Panelists discuss clinical use of teplizumab including patient selection, navigating approval processes, and managing the 14-day infusion regimen to optimize outcomes and delay the progression of type 1 diabetes.

Panelists discuss how delaying intervention between stage II and stage III T1D can result in irreversible β-cell loss, higher rates of complications, and poorer overall outcomes for patients.

Panelists discuss how understanding the stages of type 1 diabetes (T1D) progression is crucial for early intervention, with a focus on delaying disease advancement through proactive treatments like teplizumab.

Panelists discuss how delaying intervention in stage 2 T1D can lead to faster disease progression, increased risk of complications like diabetic ketoacidosis, and greater long-term burden on patient health and quality of life.

Panelists highlight the burden of type 1 diabetes including the significant physical, emotional, and financial challenges faced by patients and their families, emphasizing the need for early intervention and proactive management strategies.